TORONTO and HAIFA, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) -- . (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (“NurExone” or the “Company”), a developer of exosome-based therapies for regenerative ...
As the world grapples with the challenges of climate change and population growth, the demand for transformative agricultural technologies has never been more critical. Against this backdrop, Frontier ...